Replimune was founded in 2015 to develop novel, proprietary oncolytic immunotherapies for the treatment of cancer. Replimune is developing both single agent therapies and therapies that work in combination with immune checkpoint blockade, and with other immune-modulatory approaches. Replimune went public in July 2018 (NASDAQ: REPL).

Headquarters Woburn, MA
Pipeline Phase 1 clinical trials
Twitter @Replimune​